Filing Flows › Arbutus Biopharma (ABUS) › Stock forecast & fair value
Arbutus Biopharma (ABUS) stock forecast and price target
Arbutus Biopharma (ABUS) trades at $3.65. One analyst's price target is $5.40 (+48%).
Arbutus Biopharma's latest quarter
Arbutus Biopharma, Q2 2026: revenue $1.0M (-91% year over year), operating margin -588.2%, net loss $5.1M, operating cash flow −$6.0M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for ABUS stock?
One analyst's 12-month target is $5.40, +48% from $3.65. The average rating is none.
Does Arbutus Biopharma usually beat earnings estimates?
It beat the consensus EPS estimate in 50% of the quarters on record.
Is ABUS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.